MRK - Merck & Co., Inc.
| Previous Close | 83.97 |
| Open | 84.74 |
| Bid | 85.25 x 800 |
| Ask | 85.45 x 800 |
| Day's Range | 84.32 - 85.87 |
| 52 Week Range | 66.10 - 87.35 |
| Volume | 22,546,994 |
| Avg. Volume | 9,863,193 |
| Market Cap | 218.041B |
| Beta (3Y Monthly) | 0.32 |
| PE Ratio (TTM) | 23.88 |
| EPS (TTM) | 3.57 |
| Earnings Date | Oct 29, 2019 |
| Forward Dividend & Yield | 2.20 (2.62%) |
| Ex-Dividend Date | 2019-09-13 |
| 1y Target Est | 96.33 |
- Reuters
US STOCKS-Wall St gains on stimulus cues, U.S.-China trade progress
U.S. stocks ticked higher on Friday, as cues of easing monetary policy around the globe and signs of further co-operation on Sino-U.S. trade talks kept the S&P 500 within 1% of a record high. China cut its new one-year benchmark lending rate for the second month in a row, days after the Federal Reserve and the European Central Bank reduced borrowing costs and left the door open for further monetary stimulus. The S&P 500 and Nasdaq were set to end the week little changed after a rough start, sparked by attacks on Saudi oil facilities.
- GlobeNewswire
BriaCell Announces Private Placement of up to $600,000
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce a non-brokered private placement (the “Private Placement”) of up to approximately 8,571,428 common shares in the capital of the Company for gross proceeds of up to approximately C$600,000 at a price per common share of C$0.07. The closing of the Offering is scheduled to occur on or about September 26, 2019. All securities issued under the Private Placement will be subject to a hold period expiring 4 months plus 1 day following the closing date of the Private Placement.
- Zacks
Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.
- PR Newswire
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with ...
- Business Wire
Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
Approvals Based on Findings from the Phase 3 DRIVE-SHIFT Trial Evaluating a Switch to DELSTRIGO
- GlobeNewswire
BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®
Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress. Publicly-traded securities of BriaCell Therapeutics Corp. (BCT.V) (BCTXF) will remain halted for the duration of CEO Dr. Williams’ presentation. Robust responder experienced a highly remarkable reduction in breast cancer tumors in the adrenal gland and the outer lining of the brain – tumors that had metastasized to areas outside of her breasts. Prior to the Combination Study of Bria-IMT™ with KEYTRUDA®, she had failed prior regimens with 16 agents (13 chemotherapy and 3 hormonal).
- InvestorPlace
Dow Jones Today: Fed Obliges, Stocks Don’t
As was widely expected, the Federal Reserve lowered interest rates today by 25 basis points, but that wasn't enough to spark upside for equities. Nor was it enough for President Donald Trump who criticized the Fed for lacking "sense" and "vision" because it didn't lower rates by 50 basis points.Source: rafapress / Shutterstock.com Three Fed governors voted against today's rate cut, prompting some investors to express concern about the path forward."In determining the timing and size of future adjustments to the target range for the federal funds rate, the Committee will assess realized and expected economic conditions relative to its maximum employment objective and its symmetric 2 percent inflation objective," the Federal Open Market Committee wrote in a statement.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis assessment will take into account a wide range of information, including measures of labor market conditions, indicators of inflation pressures and expectations, and readings on financial and international developments.So today the Nasdaq Composite slipped 0.1% while the S&P 500 added just 0.03%. The Dow Jones Industrial Average gained 0.1%. In late trading, half of the Dow stocks were pointed higher. The only sector in the U.S. that closed higher today was, unsurprisingly, utilities. Small Winners CircleThere weren't many Dow winners today and among that small group, the gains were, well, small. One surprise was JPMorgan Chase (NYSE:JPM). Financial services stocks usually benefit from higher interest rates, and JPM and its rival banks have recently been complaining about the effects lower rates have on their net interest margins. In late trading JPM was the only financial services name in the Dow trading higher. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Another surprise, though of the disappointing variety, was Merck (NYSE:MRK). This Dow component barely nudged higher despite some encouraging news about its Keytruda cancer treatment. Regulators in Australia, Canada and the U.S. approved Keytruda to treat advanced endometrial carcinoma.This is significant news, but the stock barely moved higher today. Hey, it's not everyday three major developed markets approve a cancer treatment on the same day."Merck said regulators approved the use of Keytruda with a drug called Lenvima, discovered by the Japanese company Eisai (OTCMKTS:ESALY), to treat some instances of advanced endometrial carcinoma, a serious condition for which patients currently have few options," Josh Nathan-Kazis wrote for Barron's.Procter & Gamble (NYSE:PG) was a Dow winner today, and like the others, it was in modest fashion. P&G is one of the Dow's best-performing names this year. And some traders are getting bullish about options on the consumer goods giant's shares. Apple, AgainYes, Apple (NASDAQ:AAPL) has been making a lot of appearances here in recent days -- and the iPhone maker is back today. Wedbush released a note earlier today forecasting 185 million in iPhone 11 shipments for fiscal 2020. Analysts also wrote that pre-orders for the phone in the U.S. have been strong.Up nearly 8% this month, Apple has been one of the best-performing Dow stocks in September. Bottom Line on the Dow Jones TodayIt's clear that market participants are focusing on the Fed's division. However, because the central bank did not cut by 50 basis points today, it has another 25 basis point cut in its back pocket. Chairman Jerome Powell overtly said that the Fed can deploy more rate reductions if the economy sours, which he doesn't see happening right now.Speaking of the economy, the Fed upped its 2019 gross domestic product forecast to growth of 2.2%. That's up slightly from June's estimate of 2.1%. For now, the central bank is standing firm on its forecast of 2% GDP growth in 2020.As of this writing, Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post Dow Jones Today: Fed Obliges, Stocks Don't appeared first on InvestorPlace.
- InvestorPlace
10 Companies Making Their CEOs Rich
The headline "The Stock-Buyback Swindle" says it all. The Atlantic magazine's August issue had a story about how American companies are spending trillions on stock buybacks to enrich their CEOs. Much of the article's content has been covered extensively by business media -- both the pros and cons -- so I won't rehash the arguments. However, one of author Jerry Useem's paragraphs bears repeating because it hits at the core of the problem."Corporations describe the practice as an efficient way to return money to shareholders," Useem wrote. "By reducing the number of shares outstanding in the market, a buyback lifts the price of each remaining share. But that spike is often short-lived: A study by the research firm Fortuna Advisors found that, five years out, the stocks of companies that engaged in heavy buybacks performed worse for shareholders than the stocks of companies that didn't."InvestorPlace - Stock Market News, Stock Advice & Trading TipsI've always believed that if a company wants to allocate its free cash flow to shareholders, it should do so by paying a special dividend, not by repurchasing shares or paying a regular dividend. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Stock buybacks distort earnings growth while regular quarterly dividends ratchet up shareholder expectations. Neither is good for the long-term health of a business. But it's especially galling when stock buybacks enrich a CEO at the expense of the rank-and-file employees.Love them or hate them, these 10 companies are making their CEOs rich. Stock Buybacks Making CEOs Rich: Oracle (ORCL)Source: JHVEPhoto / Shutterstock.com According to the Equilar 200 study, Oracle (NASDAQ:ORCL) co-CEOs Mark Hurd and Safra Catz earned a combined $298 million in total compensation in fiscal 2017 and 2018, of which approximately 96% came from stock grants and option awards. In 2018, Hurd and Catz were paid 1,205 times the company's median pay of $89,887. As a tandem, Hurd and Catz own 49.7 million shares, which are worth $2.7 billion at current prices. The duo's compensation in 2017 and 2018 fails to take into consideration the amount paid through vested shares. Catz received $158 million in shares that vested in fiscal 2018 alone. As for share repurchases, the company repurchased $51 billion of its stock over the past three fiscal years, reducing its share count by 14%. Not surprisingly, its earnings per share increased by 43% over the same period. JPMorgan (JPM)Source: Bjorn Bakstad / Shutterstock.com JPMorgan (NYSE:JPM) CEO James Dimon earned $58 million in total compensation in fiscal 2017 and 2018, approximately 77% of it from stock grants. In 2018, Dimon was paid 381 times the company's median pay of $78,923.Dimon owns 10 million shares if you include options, which are worth $1.2 billion at current prices. In 2018 alone, the JPMorgan CEO had $11 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $44.5 billion of its stock over the past three fiscal years, reducing its share count by 10%. JPMorgan increased its earnings per share by 50% over the same period. Microsoft (MSFT)Source: gguy / Shutterstock.com Microsoft (NASDAQ:MSFT) CEO Satya Nadella earned $46 million in total compensation in fiscal 2017 and 2018, approximately 61% of it from stock grants and option awards. In 2018, Nadella was paid a relatively reasonable 154 times the company's median pay of $167,689.Nadella owns 2.9 million shares if you include options, which are worth $393.6 million at current prices. In 2018 alone, Nadella had $25.8 million in Microsoft stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $42 billion of its stock over the past three fiscal years, reducing its share count by 3%. That's not surprising given how much stock the company issues to employees for a job well done. Microsoft managed to increase its earnings per share by 98% over the same period. Merck (MRK)Source: JHVEPhoto / Shutterstock.com Merck (NYSE:MRK) CEO Kenneth Frazier earned $38 million in total compensation in fiscal 2017 and 2018, approximately 68% of it from stock grants and option awards. In 2018, Frazier was paid 215 times the company's median pay of $82,173.Frazier owns 3.7 million shares if you include options, which are worth $307.5 million at current prices. In 2018 alone, the Merck CEO had $41.3 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $16.5 billion of its stock over the past three fiscal years, reducing its share count by 6%. Merck managed to increase its earnings per share by 49% over the same period. However, its GAAP results have been very choppy over the past decade. You'll want to take this with a grain of salt. Apple (AAPL)Source: View Apart / Shutterstock.com According to the 2018 version of the Equilar 200, a list of the 200 highest-paid CEOs in America, Apple (NASDAQ:AAPL) CEO Tim Cook made $29 million in total compensation in fiscal 2017 and 2018, none of it from stock grants or options. In 2018, Cook was paid 283 times the company's median pay of $55,426. However, one needn't feel sorry for Cook. He owns 878,425 shares of Apple stock worth $198 million as (as of Sept. 12). In addition, Cook has had more than a million shares of AAPL stock vest in the last two years alone. This means his compensation for 2017 and 2018 was actually much higher than $29 million. As for share repurchases, the company repurchased $135.3 billion of its stock over the past three fiscal years, reducing its share count by 14%. Not surprisingly, its earnings per share increased by 29% over the same period. Bank of America (BAC)Source: 4kclips / Shutterstock.com Bank of America (NYSE:BAC) CEO Brian Moynihan earned $43 million in total compensation in fiscal 2017 and 2018, approximately 93% of it from stock grants and option awards. In 2018, Moynihan was paid 247 times the company's median pay of $92,040.Moynihan owns 3.4 million shares if you include options, which are worth $100.9 million at current prices. In 2018 alone, Moynihan had $23.1 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $38 billion of its stock over the past three fiscal years, reducing its share count by 9%. Bank of America increased its earnings per share by 99% over the same period. eBay (EBAY)Source: Mano Kors / Shutterstock.com eBay (NASDAQ:EBAY) CEO Devin Wenig earned $36 million in total compensation in fiscal 2017 and 2018, approximately 82% of it from stock grants and option awards. In 2018, Wenig was paid a 152 times the company's median pay of $119,562.Wenig owns 1.7 million shares if you include options, which are worth $67.5 million at current prices. In 2018, Wenig had $18.8 million in eBay stock vest on top of his total compensation. As for share repurchases, the company repurchased $10.1 billion of its stock over the past three fiscal years, reducing its share count by 19%. eBay increased its earnings per share by 80% over the same period. Qualcomm (QCOM)Source: photobyphm / Shutterstock.com Qualcomm (NASDAQ:QCOM) CEO Steven Mollenkopf earned $32 million in total compensation in fiscal 2017 and 2018, approximately 75% of it from stock grants and option awards. In 2018, Mollenkopf was paid a 233 times the company's median pay of $85,592.Mollenkopf owns 679,813 shares if you include options, which are worth $53.8 million at current prices. In 2018 alone, the CEO had $12.9 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $27.8 billion of its stock over the past three fiscal years, reducing its share count by 11%. Qualcomm decreased its earnings per share by 203% over the same period. On a non-GAAP basis, it decreased earnings per share by 21%. Pfizer (PFE)Source: Manuel Esteban / Shutterstock.com Pfizer (NYSE:PFE) CEO Ian Read earned $46 million in total compensation in fiscal 2017 and 2018, approximately 76% of it from stock grants and option awards. In January 2019, Read passed down the company to Albert Bourla after eight years at Pfizer's helm. In 2018, Read was paid 244 times the company's median pay of $80,011.Read owns 1.3 million shares if you include options, which are worth $48.5 million at current prices. In 2018 alone, Read had $10.6 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $22.2 billion of its stock over the past three fiscal years, reducing its share count by 5%. Pfizer increased its earnings per share by 68% over the same period. Cisco (CSCO)Source: Sundry Photography / Shutterstock.com Cisco (NASDAQ:CSCO) CEO Charles Robbins earned $38 million in total compensation in fiscal 2017 and 2018, approximately 73% of it from stock grants and option awards. In 2018, Robbins was paid 160 times the company's median pay of $132,764, the second-highest median pay (behind Microsoft) of the 10 stocks listed in this article. Robbins owns 139,189 shares if you include options, which are worth $6.9 million at current prices. Of the CEOs on this list, Robbins has the smallest ownership position in terms of total dollars in stock held. In 2018, Robbins had $9 million in stock vest on top of his total compensation for the year. As for share repurchases, the company repurchased $41.9 billion of its stock over the past three fiscal years, reducing its share count by 13%. Cisco increased its earnings per share by 24% over the same period. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post 10 Companies Making Their CEOs Rich appeared first on InvestorPlace.
- Zacks
Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma
Merck (MRK) receives accelerated approval for label expansion of Keytruda in combination with Lenvima for treating certain types of endometrial carcinoma. Its Ebola vaccine BLA gets priority review.
- Benzinga
NewLink Genetics Rallies After Ebola Vaccine Granted Priority Review Status
Potential approval of the vaccine will trigger issuance of a priority review voucher owned by Merck and in which NewLink has a substantial economic interest. The priority review voucher program was created by the U.S. Congress in 2007, and under the program, on approval of a treatment for a neglected or rare pediatric disease, the developer will be issued a voucher for priority review for a different drug as a means of incentivizing development of treatments for neglected and rare diseases. "We are pleased with this morning's announcement from our partner, Merck.
- Business Wire
FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High or Mismatch Repair Deficient , Who Have Di
- Zacks
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Merck (MRK) closed at $82.51, marking a +0.59% move from the previous day.
- Zacks
Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
The FDA accepts Seattle Genetics (SGEN) and Astellas' BLA for enfortumab vedotin under a priority review to treat advanced/metastatic urothelial cancer. A verdict is pending on Mar 15, 2020.
- Zacks
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
- Business Wire
FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review for Merck’s investigational Ebola vaccine (V920), under review for the prevention of disease caused by the Ebola Zaire virus. In July 2016, the FDA granted Breakthrough Therapy Designation to V920.
- American City Business Journals
A look inside Merck's new Peninsula research 'superhub'
Merck's new facility in South San Francisco is designed to showcase the best the Bay Area biotech community has to offer — both internally as it consolidates staff there and externally as it seeks a bridge to young, innovative companies.
- Zacks
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
- Zacks
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
- InvestorPlace
3 Big Stock Charts for Monday: Merck, Facebook and Microsoft
The market didn't end last week on a high note, but then again, it didn't need to. Even with Friday's 0.07% setback for the S&P 500, the index still mustered just a little less than a 1% advance for the five-day stretch. That makes a third winning week in a row.Source: Shutterstock Oversized Apple (NASDAQ:AAPL) is the reason the broad market could get up and over the hump, falling nearly 2% in Friday's action after investors rethought the costs related to the company's strategy of attracting people to its hardware and new streaming service. That impact was more than smaller names like General Electric (NYSE:GE) could offset. GE was up nearly 1% on the last day of last week, buoyed by optimism surrounding what should amount to a $5 billion debt reduction, funded by asset sales. * 10 Recession-Resistant Services Stocks to Buy As for names worth exploring as Monday's action gets going, however, the stock charts of Facebook (NASDAQ:FB), Microsoft (NASDAQ:MSFT) and Merck (NYSE:MRK) are of the most interest. Here's why.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Microsoft (MSFT)There's no denying Microsoft shares have been one of the market's best and most reliable performers for years now. Even the headwind that hammered most names late last year wasn't horrific for MSFT stock, and shares recovered quite nicely this year from that lull.This year's overheated rally looks like it has run its full course though, progressing even faster than the 2017/2018 gain. Although it's not past the point of no return yet, the action since late July suggests the bears are taking their shot. They've been nice enough to leave clear clues. * Click to EnlargeThe biggest clue to speak of is the converging wedge shape that's formed since July. The lower boundary, plotted in blue, traces all the lows going back to December's low. * Although not overwhelmingly so, the volume tide has started to lean bearishly. Should the Chaikin line on the weekly chart fall under zero, that may be the proverbial tipping point. * As for a plausible downside target, the past two major setbacks have pulled Microsoft shares just below the 200-day moving average line, marked in white on both stock charts. Merck (MRK)Shares of drugmaker Merck have dished out a healthy, even if at times uneven, rally over the course of the past year and a half. Even factoring in the current lull, MRK stock is still up 56% from its early 2018 low.The complexion of that advance has slowly but surely -- maybe even imperceptibly -- taken a turn for the worst though. While still seemingly in bullish mode, the momentum is fading and the pokes at key technical floors are more frequent and more potent. * 7 Tech Stocks You Should Avoid Now * Click to EnlargeThe slowdown of the advance is easily indicated on the daily chart, with each resistance line, marked in yellow, plotted at a shallower direction than the prior one. * It's not a detail even the most focused of chart watchers would notice or care about, but each peak of the Chaikin line since the beginning of this year has been lower than the past, underscoring the slowdown. Ditto for the MACD crossunders. * So far the 200-day moving average line, marked in white on both stock charts, has held up as a floor. The straight-line support that tags all the key lows since early 2018, however, was tested again last week. That's the make-or-break level, marked as a dashed blue line on the weekly chart. Facebook (FB)It's interesting. All stock charts demonstrate some degree of interplay with their moving average. Sometimes it means a lot, and sometimes it means little. It's something that at the very least has to be respected though.To that end, Facebook has been strangely responsive to its moving average line, sometimes being stopped and reversed at them, and other times being blasted past them when they're passed. That's what makes the past couple of weeks so curious … and a little bearish. * Click to EnlargeThe chief worry here is how FB stock tested but failed to hurdle the 50-day moving average line, plotted in purple on both stock charts, this month. As the daily chart shows, the 50-day line has been a biggie. * That being said, there are still a couple of other, albeit less meaningful, moving average lines that have been boundaries in the past that could become a boundary again. * Fueling the prospect of more downside is the fact that, over the long haul, FB stock is no stranger to major moves. The stock is still closer to being overbought than not from this year's rebound move, as indicated by the weekly chart's RSI tool.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Recession-Resistant Services Stocks to Buy * 7 Hot Penny Stocks to Consider Now * 7 Tech Stocks You Should Avoid Now The post 3 Big Stock Charts for Monday: Merck, Facebook and Microsoft appeared first on InvestorPlace.
- GlobeNewswire
BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia
BERKELEY, Calif., Sept. 16, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in.
- Zacks
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
- Zacks
Renal Cell Carcinoma Space in Focus: Some Key Developments
The first-line RCC treatment landscape is gradually changing. Let's take a look at the recent events in this space.
- Zacks
Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised)
Roche's (RHHBY) immuno-oncology drug, Tecentriq, meets the primary goal in a late-stage study in NSCLC patients. Also, the company reports positive data on its NMOSD drug in a phase III study.
- Yahoo Finance Video
What's next for Purdue Pharma after filing for bankruptcy
Oxycontin maker Purdue Pharma filed for chapter 11 bankruptcy on Sunday, after reaching a tentative settlement with 24 states that accused the company of fueling the U.S. opioid crisis. Yahoo Finance's Alexis Keenan reports. William Soilman, Chairman and CEO of the Accreditation Council for Medical Affairs, further discusses with Yahoo Finance's Adam Shapiro and Julie Hyman.
